Ipilimumab with Nivolumab in molecular-Selected patients with castration-resistant PRostate cancer: primary analysis of the Phase 2 INSPIRE trial

Sandra van Wilpe; Iris S. H. Kloots; P.H.J. Slootbeek; Martijn H. den Brok; Harm Westdorp; Maïté Franken; M. Coskuntürk; Thamara E. Osinga; H. Bloemendal; Gosse J. Adema; R J Smeenk; James Nagarajah; Jolique van Ipenburg; Leonie I. Kroeze; Marjolijn J. L. Ligtenberg; J.A. Schalken; Winald R. Gerritsen; Niven Mehra

doi:10.1016/j.annonc.2024.09.004

Abstract

This is the authors' abstract. We don't add key points for this paper.

Metastatic castration-resistant prostate cancer (mCRPC) typically exhibits resistance to immune checkpoint inhibitors (ICIs). However, a subset of mCRPC patients displays a more immunogenic profile. This study examines efficacy and safety of dual ICI therapy in molecularly selected mCRPC.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wilpe et al. (2024) studied this question.

synapsesocial.com/papers/68e59b44b6db6435875364ef https://doi.org/10.1016/j.annonc.2024.09.004

View Full Paper

Ask AI

Bookmark

Share

Ipilimumab with Nivolumab in molecular-Selected patients with castration-resistant PRostate cancer: primary analysis of the Phase 2 INSPIRE trial

Abstract

Ask about this paper

Discussion

Cite This Study

Ipilimumab with Nivolumab in molecular-Selected patients with castration-resistant PRostate cancer: primary analysis of the Phase 2 INSPIRE trial

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading